Idiopathic
“Idiopathic” is a term used in medicine to describe a disease or condition that arises spontaneously or for which the cause is unknown.
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.
Overview
The term “idiopathic” is used in the medical field to describe a condition or disease that arises spontaneously or for which the cause is unknown. The word originates from the Greek words “idios,” meaning “one’s own” or “private,” and “pathos,” meaning “suffering” or “disease.” Essentially, when a condition is labeled idiopathic, it means that, despite thorough medical evaluation and testing, no identifiable cause or underlying mechanism has been determined. The use of “idiopathic” underscores the complexity of medical conditions and the limitations of current medical knowledge in pinpointing specific etiologies for certain diseases. Understanding idiopathic conditions often involves ongoing research and may eventually lead to the discovery of specific causes or contributing factors, which can then refine the classification and treatment of these conditions.
Idiopathic Conditions
Idiopathic conditions are diagnosed after other potential causes have been systematically ruled out. This term is often used in various medical specialties. For example:
Idiopathic Pulmonary Fibrosis (IPF): A chronic and progressive lung disease characterized by the thickening and scarring (fibrosis) of lung tissue without a known cause.
Idiopathic Thrombocytopenic Purpura (ITP): An autoimmune disorder that leads to an abnormally low number of platelets in the blood, resulting in excessive bruising and bleeding, where no specific cause can be identified.
Idiopathic Scoliosis: A type of scoliosis (curvature of the spine) that appears in otherwise healthy children and adolescents and has no known cause.
Idiopathic Intracranial Hypertension (IIH): A condition characterized by increased pressure around the brain without an identifiable cause.
Future Directions
Emerging evidence suggests potential links between the microbiome and various idiopathic conditions. For idiopathic pulmonary fibrosis (IPF), there is growing interest in the lung microbiome, with some studies identifying microbial dysbiosis in IPF patients that may contribute to inflammation and fibrosis, though further research is needed to establish causality. In idiopathic thrombocytopenic purpura (ITP), the gut microbiome has been implicated in autoimmune disorders, suggesting that alterations in gut microbiota may influence ITP development by impacting immune function. The link between the microbiome and idiopathic scoliosis is less studied, but recent studies have found that microbiome-induced changes play a causal role in the etiology of the condition. [1] In summary, while emerging evidence suggests possible microbiome-related causes for these idiopathic conditions, more rigorous scientific investigation is needed to clarify these potential links.
Scoliosis, a spinal curvature over 10°, is influenced by gut microbiome variations, affecting spinal, respiratory, and cardiovascular health.
References
- Causal effects of gut microbiota on scoliosis: A bidirectional two-sample mendelian randomization study.. Lai B, Jiang H, Gao Y, Zhou X.. (Heliyon. ( Oct 27. 2023))
Lai B, Jiang H, Gao Y, Zhou X.
Causal effects of gut microbiota on scoliosis: A bidirectional two-sample mendelian randomization study.Heliyon. ( Oct 27. 2023)